The Story Behind GHK

Imagine a reality in which cancer, even metastatic cancer, is not a scary illness and it could be easily cured with a non-toxic and inexpensive treatment. Imagine a reality in which organ shut down is just a temporary situation and there is an inexpensive and simple treatment that causes the organ to repair itself.  Imagine a reality in which Alzheimer and Chronic Obstructive Pulmonary Disease (COPD) could be cured. Imagine a reality in which wounds in diabetic people could easily heal. Imagine a reality in which people could live longer, be healthy, and look younger at a minimal cost.  It might sound like science fiction, but the fact is that we have the science that may cure many illnesses in a way that is safe, non-toxic, and inexpensive. Recent research suggests that a GHK, a copper binding peptide, may be the miracle we have all been looking for. The man behind this discovery, Dr. Loren Pickart, is racing to get it out to the public. 

Dr. Loren Pickart (born 1938) came a long way from Winona, MN, where he was born, to Bellevue, WA where he is now, working to complete his GHK research. At the age of 10, suffering from a strep throat, he experienced his first scientific marvel when a doctor gave him a penicillin shot that made him felt better within a few hours. Between the years 1956 to 1959 he served in the US Army, working at  Fort Huachauca, Arizona with scientists and engineers on the Decca project; the navigation system that later evolved to GPS. After his military service he went back to Minnesota to start college. For a while he considered studying history, but then decided to learn chemistry and math. “Back in that day” he recalls the atmosphere in the early sixties,“medical researchers believed that after ten years of research we will find cure for cancer and heart disease, and there will be no jobs in medical research.” After graduation he moved to Santa Barbara, CA where he worked on anti-aging research. Later he received his PhD in biochemistry from University of California San Francisco.

During his work on anti-aging in Santa Barbara Dr. Pickart compared blood of young medical students, between the ages of 20-25, with blood taken from older people, between the ages 50-70. He noticed that the blood of the older people produced different amounts of blood proteins than the young students. He also compared liver tissues of young people versus older people, and found similar results. When he incubated the old liver tissues with younger blood, the old tissues started to synthesize proteins like the younger tissues. The cells reversed their aging effects and became more like younger cells. When he incubated the younger tissues with the older blood, the young cells produced proteins like older liver tissue. When he worked in UCSF, Dr. Pickart kept on trying to isolate the specific component in the younger blood that has this power to regress the effects of aging on the liver cells. In 1973 he found his answer when he discovered the human tripeptide GHK (Glycyl-L-Histidyl-L-Lysine), the copper binding peptide

In 1980 Dr. Pickart moved to Seattle, WA to work at the Benaroya Institute. He received research grants from the National Cancer Institute to further develop his research on GHK. In 1985, he and his business partner, Barbara Weinstein, established a company, ProCyte, to develop GHK products for hair transplantation, dermatological healing, and for anti-aging cosmetics.  ProCyte was later sold to another company but the products are still sold and used. In 1994 Dr. Pickart established a new company, Skin Biology, to develop GHK products that would provide better healing for infected wounds.  For his research he worked with a local veterinarian, treating horses with barbwire wounds with great results. Pharmaceutical companies, however, showed little interest in a possible low cost way of healing skin ulcers. After this, Dr. Pickart focused on trying to understand the possible potential uses of GHK. Today Skin Biology is a cosmetics company that uses GHK to develop different anti-aging products.

GHK's research breakthrough came in 2010, when the Broad Institute (Harvard and MIT) determined the effects of GHK on human gene expression. Studies from Singapore, which used the Broad Institute system to find the best treatment for metastatic colon cancer, predicted that GHK, at a low and non-toxic level, would reverse the gene expression pattern that caused colon cancer. Dr. Pickart explains: “Cancer cells survive by suppressing the programmed cell death apoptosis system. Cells have "checkpoints" to determine if DNA is made properly and if it is not, the programmed cell death system terminates the cell”.  Later studies at the University of Alabama found that GHK, at a very low level, did not harm certain normal cells, but acted to reset the programmed cell death in human cancer cells and inhibit their growth. 

colon cancer

In 2012, four universities; University of British Columbia, Boston University, University of Pennsylvania, and the University of Groningen, studied the gene expression in cells from patients with severe emphysema in chronic obstructive lung disease (COPD). COPD is the third largest cause of death in the US (after heart attacks and cancer). The Broad Institute's computers indicated that GHK would shift the gene output and shut down tissue destructive genes while increasing the output of genes associated with tissue healing and remodeling. This prediction was confirmed when tested on cells from patients with the disease, where GHK, at a very low and non-toxic level, shifted the cellular genes patterns from tissue destruction to tissue repair. 

lungs with COPD
Since Dr. Pickart’s initial discovery in 1973, GHK  research has been growing internationally, in the academic world, the biotech industry, and the cosmetics industry. The research provides many successful results that hopefully one day would lead to better life quality of people and animals.  In the past Dr. Pickart’s GHK research received many grants. These days, with no research grants, Dr. Pickart finances his own research from the profits of his cosmetics company Skin Biology.  He is working hard with his team of scientists to finish his book about GHK. He wants his research, findings and knowledge to be recorded for the sake of human kind. GHK could have a very broad anti aging and anti disease effect.” He says. He is very much dedicated to his research, and has no plans to retire. Since drug approvals are slow and very costly in the USA, Dr. Pickart will happily give advice to physicians and scientists in other countries where introducing GHK into medical treatment my help improve human life.

Skin Biology 3% GHK VIP Luxury Cream

3% GHK VIP Luxury cream is the most recent product that Dr. Pickart developed for his Skin Biology skin care line. The cream is a result of many years of research of copper peptide and its anti aging effect. This is the only cream in the market today that  contains the most potent concentration of GHK - the body's natural copper peptide. 3% GHK VIP Luxury cream is designed to treat effectively a wide range of skin concerns from blemishes to wrinkles. Regular use results a radiant, tightened and healthy young look.  Since it was released on the market in December 2013, it became a best seller among Dr. Pickart’s clients. Skin Biology is about to release 3% GHK VIP Luxury Serum.

Recommended Articles by Dr. Pickart:

Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, et al. (2012) A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Med 4: 67.

Hong Y, Downey T, Eu KW, Koh PK, Cheah PY (2010) A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 27: 83-90.

Matalka LE, Ford A, Unlap MT (2012) The tripeptide, GHK, induces programmed cell death in SH-SY5Y neuroblastoma cells. J Biotechnol Biomater 2: 1-4.

Meiners S, Eickelberg O (2012) Next-generation personalized drug discovery: the tripeptide GHK hits center stage in chronic obstructive pulmonary disease. Genome Med 4: 70.

Pickart L (2009) Chapter 36: The Human Tripeptide GHK (Glycyl-L-Histidyl-L-Lysine), The Copper Switch, and The Treatment of the Degenerative Conditions of Aging. In: Klatz R, Goldman R, editors. Anti-Aging Therapeutics XI. Chicago, IL, USA: American Academy of Anti-Aging Medicine. pp. 301-312.

Pickart L, Margolina A (2012) Anti-Aging Activity of the GHK Peptide - The skin and beyond. J Aging Res Clin Pract 1: 13-16.

Pickart L, Vasquez-Soltero JM, Margolina A (2012) The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev 2012: 324832.


  1. We also provide analytical services and laboratory services to our customers. Glycyl-L-Histidyl-L-Lysine


Post a Comment